Cancer Res 2007, 67:4725–4731.PubMedCrossRef 28. Wente MN, Gaida MM, Mayer C, Michalski CW, Haag N, Giese T, Felix K, Bergmann F, Giese NA, Friess H: Expression
and MRT67307 chemical structure potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol 2008, 33:297–308.PubMed 29. Ou DL, Chen CL, Lin SB, Hsu CH, Lin LI: Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with click here metastasis and radiotherapy. J Pathol 2006, 210:363–373.PubMedCrossRef 30. Held-Feindt J, Rehmke B, Mentlein R, Hattermann K, Knerlich F, Hugo HH, Ludwig A, Mehdorn HM: Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia 2008, 56:764–774.PubMedCrossRef 31. Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, et al.: CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 2012, 72:3546–3556.PubMedCrossRef 32. Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735–6741.PubMedCrossRef 33. Sakamoto K, Masuda {Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|buy Anti-cancer Compound Library|Anti-cancer Compound Library ic50|Anti-cancer Compound Library price|Anti-cancer Compound Library cost|Anti-cancer Compound Library solubility dmso|Anti-cancer Compound Library purchase|Anti-cancer Compound Library manufacturer|Anti-cancer Compound Library research buy|Anti-cancer Compound Library order|Anti-cancer Compound Library mouse|Anti-cancer Compound Library chemical structure|Anti-cancer Compound Library mw|Anti-cancer Compound Library molecular weight|Anti-cancer Compound Library datasheet|Anti-cancer Compound Library supplier|Anti-cancer Compound Library in vitro|Anti-cancer Compound Library cell line|Anti-cancer Compound Library concentration|Anti-cancer Compound Library nmr|Anti-cancer Compound Library in vivo|Anti-cancer Compound Library clinical trial|Anti-cancer Compound Library cell assay|Anti-cancer Compound Library screening|Anti-cancer Compound Library high throughput|buy Anticancer Compound Library|Anticancer Compound Library ic50|Anticancer Compound Library price|Anticancer Compound Library cost|Anticancer Compound Library solubility dmso|Anticancer Compound Library purchase|Anticancer Compound Library manufacturer|Anticancer Compound Library research buy|Anticancer Compound Library order|Anticancer Compound Library chemical structure|Anticancer Compound Library datasheet|Anticancer Compound Library supplier|Anticancer Compound Library in vitro|Anticancer Compound Library cell line|Anticancer Compound Library concentration|Anticancer Compound Library clinical trial|Anticancer Compound Library cell assay|Anticancer Compound Library screening|Anticancer Compound Library high throughput|Anti-cancer Compound high throughput screening| T, Mita S, Ishiko T, Nakashima Y, Arakawa H, Egami H, Harada S, Matsushima K, Ogawa M: Interleukin-8 is constitutively and commonly produced by various human carcinoma cell-lines. Int J Clin Lab Res 1992, 22:216–219.PubMedCrossRef 34. Inoue
K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000, 60:2290–2299.PubMed 35. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G: Interleukin-8 in non-small cell lung carcinoma: relation with Racecadotril angiogenic pattern and p53 alterations. Lung Cancer 2005, 50:309–317.PubMedCrossRef 36. Benoy IH, Salgado
R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY: Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004, 10:7157–7162.PubMedCrossRef 37. Ren Y, Poon RT, Tsui HT, Chen WH, Li Z, Lau C, Yu WC, Fan ST: Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003, 9:5996–6001.PubMed 38. Liu Z, Yang L, Xu J, Zhang X, Wang B: Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res 2011, 166:241–246.PubMedCrossRef 39. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T: Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 2005, 12:800–807.PubMedCrossRef 40. Fabregat I, Roncero C, Fernandez M: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007, 27:155–162.PubMedCrossRef 41.
Related posts:
- J Immunol Methods 2005, 298: 61–72 PubMedCrossRef 19 Lin W, Vosk
- Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis
- Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
- J Cell Physiol 2006, 207:520–529 PubMedCrossRef
8 Caloge - Gastroenterology 2005, 128:1229–1242 PubMedCrossRef 11 Torres LE